



Summary

[Expert Opinion on Pharmacotherapy](#)

December 2007, Vol. 8, No. 18, Pages 3133-3146
(doi:10.1517/14656566.8.18.3133)

Management of glioblastoma

Tomokazu Aoki^{†1} MD, PhD, Nobuo Hashimoto² & Masao Matsutani³

¹Kitano Hospital, Department of Neurosurgery, Brain Tumour Center, 2-4-20 Ohgimachi, Kita-ku, Osaka, Japan +81 6 6312 1221; +81 6 6361 0588; tomokazu@kitano-hp.or.jp

²Kyoto University, Department of Neurosurgery, 54 Kawaracho, Shougoinn, Sakyo-ku, Kyoto, Japan

³Saitama Medical University, Department of Neurosurgery and Neuro-Oncology, International Medical Center, 1397-1 Yamane Hidaka-shi, Saitama, Japan

[†] Author for correspondence

Glioblastoma multiforme (GBM) are among the most devastating neoplasms claiming the lives of patients within a median of 1 year after diagnosis. Treatment of GBM requires a multidisciplinary approach. Treatments include surgery, radiotherapy, chemotherapy and so on. Temozolomide (TMZ) has emerged as an active agent against malignant gliomas. On the basis of the work by the European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada, concurrent radiotherapy and the oral alkylating agent TMZ followed by adjuvant TMZ has become the standard of care for patients with newly diagnosed GBM, although the methylation status of the O⁶-methylguanine-DNA methyltransferase promoter is predictive for survival of GBM patients. Gliadel is a biodegradable polymer wafer impregnated with carmustine. Gliadel has been one of the few treatment modalities to demonstrate a statistical benefit in patients with malignant glioma. These new FDA approved drugs advanced the treatment of malignant glioma, but more progress is needed. Patients require improvements in chemotherapy, surgery, radiotherapy, molecular targeted therapy, immunotoxin using the convection-enhanced delivery and more.

[Full Text](#) [PDF \(281 KB\)](#) [PDF Plus \(308 KB\)](#)

[Home](#) > [Journal home](#) > [TOC](#) > Summary

[Prev. Article](#) | [Next Article](#)

[View/Print PDF \(281 KB\)](#)

[View PDF Plus \(308 KB\)](#)

[Add to favourite](#)

[Email to a friend](#)

[RSS](#) | [TOC Alert](#) | [Citation Alert](#)

[What is RSS?](#)

Quick Links

- Alert me when:
[New articles cite this article](#)
- [Download to citation manager](#)
- Related articles found in:
[Expert Opinion series](#)
- [View Most Downloaded Articles](#)

Quick Search

Expert Opinion series for

Authors:

- Tomokazu Aoki
- Nobuo Hashimoto
- Masao Matsutani

Keywords:

- chemotherapy
- gliadel
- glioblastoma
- molecular targeted therapy
- radiotherapy
- surgery
- temozolomide
- tumour targeted toxin